Implementation of maternal blood cell‐free <scp>DNA</scp> testing in early screening for aneuploidies

2013158 citationsJournal Articlebronze Open Access

Authors

M. M. Gil · Harris Birthright Research Centre for Fetal Medicine

Madlyn Ferraro · Harris Birthright Research Centre for Fetal Medicine

K. H. Nicolaides · Harris Birthright Research Centre for Fetal Medicine

Abstract

Routine screening for trisomies 21, 18 and 13 by cfDNA testing at 10 weeks is feasible and has a lower FPR than does combined testing, but abnormal results require confirmation by CVS.

Topics & Keywords

Prenatal Screening and Diagnostics Parvovirus B19 Infection Studies Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Ultrasound in Obstetrics and Gynecology

Volume 42, Issue 1, pp. 34-40

DOI: 10.1002/uog.12504

Field-Weighted Citation Impact: 49.33